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A B S T R A C T
Three small double strand siRNAs (506-MMP1, 859-MMP1 and 891-MMP1), each contains 25–26
nucleotides, with high speciﬁc to human MMP1 were designed according to mRNA sequence of human
MMP1 (NCBI, NM_002421). To monitor the MMP1 gene expression, the total RNAs of human skin
ﬁbroblast (Detroit 551, BCRC 60118) were extracted. One human matrix metalloproteinase 1 (MMP1)
partial sequence cDNA, included all the three siRNA target sequences, ampliﬁed speciﬁcally via RT-PCR
and PCR reactions, and three synthesized siRNA target DNAs were cloned individually into pAcGFP1-N3
with green ﬂuorescent protein (GFP). These reporter plasmids were then transfected individually into
malignant melanoma (MeWo, BCRC 60540) and the GFP was detected after 48h. Fluorescence results
indicated that the 859 siRNA revealed highest inhibitory ability (almost 90%), and was, accordingly,
transfected intoMeWo cells. According to the real-time quantitative PCR andwestern blot, the exhibition
ability to silence MMP1 gene expression was 85–89%.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Matrix metalloproteinase 1 (MMP1), the member of MMP
family, is a kind of zinc and calcium-dependent endopeptidase and
collagenase that are able to degrade essentially all extracelluar
matrix (ECM) components, such as basement membranes, colla-
gen, and ﬁbronectin [23,16,24]. The human MMPs family, which
consists of at least 26 proteases, can be divided into several
subgroups according to their structure and substrate speciﬁcity
[22,28]. These subfamilies include collagenases, gelatinases,
stromelysins, matrilysins, andmembrane-typeMMPs (MT-MMPs),
among others. MMPs play an important role in both physiological
and pathological conditions, including tissue regeneration, wound
repair, reproduction, arthritis, atherosclerosis, and autoimmune
blistering disorders of the skin [3]. MMPs have also been
implicated in carcinogenesis because of their ability to degrade
ECM, which is a key event in cancer progression [7]. Growing
evidence has shown that MMPs can facilitate tumor growth,
invasion, and metastasis in various cancers [7]. The ECM is
composed of collagen and elastin, and is very important for
creating the cellular environments during morphogenesis, tissue
repair and remodeling [28,16]. Degradation of ECM in skin tissue
would cause skin wrinkle [8].
The human MMPs family, which consists of at least 26
proteases, can be divided into several subgroups according to
their structure and substrate speciﬁcity [22,28]. These subfamilies
include collagenases, gelatinases, stromelysins, matrilysins, and
membrane-type MMPs (MT-MMPs). MMPs play an important role
in both physiological and pathological conditions, including tissue
regeneration, wound repair, reproduction, arthritis, atherosclero-
sis, and autoimmune blistering disorders of the skin [3]. It also
plays an important role on the malignant tumor metastasis. The
proliferation of host tumor cell is usually accompanied by
simultaneous cancer cells migration that enable them to reach
the target tissue [18]. During malignant tumor proliferation, the
neoplastic cells ﬁrstly attach to the underlying basement
membrane. After being degraded by proteases produced by
malignant cells, tumor cells pass through the basement mem-
brane, spread into adjacent connective tissue. They proliferate to
form a metastasis in target tissue and induce angiogenesis [2].
MMP1 (collagenase-1), located on chromosome 11q22, is an
important member of the MMP family that speciﬁcally degrades a
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major component of the ECM, type I collagen, as well as other
ﬁbrillar collagens of types II, III, V, and IX [13,32]. TheMMP1 gene is
expressed in various kinds of normal cells, often at low levels under
physiological conditions. However, MMP1 gene expression
increases dramatically in a large number of malignancies,
including head and neck cancer [25]. It is worth to mention that
MMP1 is very important to metastasis and invasion of tumor cells
because of its capability of degrading ﬁbrillar collagen type I and III
[26], which consequently breaks the ECM molecules.
RNA interference (RNAi) is a phenomenon of sequence-speciﬁc
post-transcriptional gene silencing (PTGS) that is a conserved
biological response. It was ﬁrst discovered by plant biologists in
1980, but its molecular mechanism kept unknown until the late
1990. Andrew Fire and Ceaig Mell studied the nematode,
Caenorhabditis elegans, and found that it is a speciﬁc silencing of
genes, highly homologous in sequence to the delivered double-
stranded RNA (dsRNA) [6]. This kind of process was considered to
be a defense mechanism against viral pathogens or uncontrolled
transposon mobilization [19,31]. The mechanism of RNAi essen-
tially involves the effectors, short (21–28 nucleotides) dsRNA, and
then degrades the target mRNA. RNAi is mediated by siRNAs that
are processed from long dsRNAs of exogenous or endogenous
origin by a cytoplasmic ribonuclease-III type called dicer [21]. The
resulting siRNAs are about 21–23 nucleotides (nt) long and then
incorporated into nuclease complex, a RNA-inducing silencing
complex (RISC). The antisense strand of siRNA serves as a template
for RISC to recognize, then targets and cleaves the mRNA
containing a sequence identical to that of the siRNA, which can
consequently then rapidly degrade mRNA [29]. In this study, 3
small double strand siRNAs (506-MMP1, 859-MMP1 and 891-
MMP1), each contains 25–26 nucleotides, with 30–50% of GC
content and high speciﬁc to human MMP1 were designed and
synthesized according to mRNA sequence of human MMP1 (NCBI,
NM_002421) and factors affecting RNA interfering efﬁciency from
previous studies [1,27,12,14,20]. To directly evaluate the silencing
efﬁciency of three siRNAs in living cells, four target genes (a long
one contained all three siRNA target DNAs and three individual
target DNAs) – green ﬂuorescent fusion protein (GFP) report
plasmids were created and examined (Fig. 1). Finally, the
quantitative PCR and western blot analyses were also carried
out to evaluate the mRNA and protein expression quantity,
respectively, of endogenous MMP1 in MeWo ﬁbroblast cells.
2. Materials and methods
2.1. Cell line and cell culture
Human embryonic skin, Detroit 551 (BCRC 60118) and
malignant melanoma of human skin, MeWo (BCRC 60540) were
purchased from Bioresource Collection and Research Center
(BCRC). The Detroit 551 cells were grown in a culture medium A
[Minimum Essential Medium Alpha Medium powder (a-MEM,
Gibco BRL) supplemented with 10% fetal bovine serum (FBS),
1.5 g/L sodium bicarbonate (Sigma)], while the MeWo cells were
grown in the same culture medium A with 1.0mM sodium
pyruvate. All cells were maintained in a humidiﬁed 37 C
incubator with 5% CO2.
2.2. RNA isolation and cDNA synthesis
Detroit 551 cells were incubated in 75mL ﬂask in cultured
medium A for 3–4 days. Total RNAwere isolated from Detroit 551
cells by using UltraspecII RNATM isolation kit (Biotecx, Houston,
TX) according to the manufacturer’s instructions. The ﬁrst strand
[(Fig._1)TD$FIG]
Fig. 1. Construction of MMP1-AcGFP1-N3 reporter plasmids. The sequence number was according to mRNA sequence of human MMP1 (NCBI, NM_002421). Bordered ATP
indicated the translation initiation codons. Shading indicated the sticky ends of multiple cloning sites of pAcGFP1-N3 vector, which was cut by HindIII and BamHI restriction
enzymes.
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of cDNA was obtained using reverse transcription-PCR. The
forward (50-ATGCACAGCTTTCCTCCACTGCT) and reverse (50-
TCAATTTTTCCTGCAGTTGAACCAGCTAT) primers, used for PCR
ampliﬁcation of human MMP1 cDNA (1410 bp), were designed
according to sequences 144–166 and 1525–1553 of NCBI:
NM_002421, respectively. Ampliﬁcation was performed using
proofreading polymerase (Gibco BRL products, Cat. No. 10,480-
010) by PCR reactions, including preincubation at 95 C for 5min,
followed by 25 cycles of 30 s at 95 C, 40 s at 50 C, 2min at 72 C
and a ﬁnal extension at 72 C for 10min, in a DNA thermal cycler
(PerkinElmer, GeneAmp PCR system 2700). PCR products were
identiﬁed using electrophoresis on 1.5% agarose gels and carried
out by ethidium bromide (EtBr). The PCR product of human
MMP1 was ﬁrst cloned into pGEM-T Easy vector (Promega) and
then transformed into Escherichia coli Top 10. After blue/white
selection and midi preparation, the DNA sequence between T/A
cloning sites of human MMP1 cDNA- pGEM-T Easy vector was
sequenced by Minshin Biotech Co., Ltd. (Taipei, Taiwan).
2.3. Construction of target MMP1 gene reporter plasmid
Three small double strand DNAs, being with 25–26 nucleotides
each, high speciﬁc to human MMP1 and 30–50% of GC content,
were predicted to be a nice target for RNA interference according to
the mRNA sequence of human MMP1 (NCBI, NM_002421) and
factors affecting RNA interfering efﬁciency from previous studies
[1,27]. To evaluate the interference efﬁcacy of potential siRNA
sequences, which were predicted to be able to block MMP1 gene
expresses, one green ﬂuorescent protein (GFP) coding plasmid,
pAcGFP1-N3 vector, was used as a reporter system. AMMP1 partial
cDNA, including all the three potent siRNA target sequences, was
constructed to the reporter vector. As shown in Fig. 1, the MMP1
cDNA (831bp), containing sequence 150–953 of MMP1 cDNA
(NM_002421), one Kozak sequence [15,4] and two restriction sites
(HindIII and BamHI), incorporated to facilitate subcloning of the
PCR product, were ampliﬁed by PCR. The human MMP1 cDNA-
pGEM-T Easy vector was used as template; and the following two
oligonucleotides, AAGCTTGCCGCCACCTGGGTAGCTTTCCTC-
CACTGCTGCTG and GGATCCGATGGGCTGGACAGGATTTTGG-
GAACGTCCATATATGGC, were used as forward and reverse
primers, respectively. After PCR reaction, the product was ﬁrst
puriﬁed and cloned into pGEM-T Easy vector (Promega), and then
transformed into E. coli Top 10. After blue/white selection and
sequence analysis, the target DNAwas subcloned into pAcGFP1-N3
vector (Clontech Laboratories, Inc.), downstream the immediate
early promoter of CMV (PCMV IE) and before the green ﬂuorescent
protein AcGFP1 coding sequences, using HindIII and BamHI cutting
sites.
According to our preliminary experiments (data not shown),
the intensity of the ﬂuorescence, expressed from MMP1 partial
cDNA-pAcGFP1-N3 plasmid (Fig. 1A), was not perfect enough for
the following assay, if the length of insert target genewas too long.
Therefore, the construction of MMP1 target gene reporter plasmid
was divided into three parts: 506-MMP1, 859-MMP1, and 891-
MMP1. As shown in Fig. 1, the 30-ends of forward and reverse
oligonucleotides were complementary (underlined) for each other,
they annealed to each other after cooling down from 95 C to 50 C.
After annealing of each pairs of oligonucleotides, two 50-sticky
ends at each annealed double strand oligonucleotide were created
and, following, they were ligated into the HindIII and BamHI
restriction sites of pAcGFP1-N3 vector. Primers used in this study
were as following:
 506-MMP1 forward: AGCTCACGCCAGATTTGCCAAGAGCAGATC
 506-MMP1 reverse: GATCGATCTGCTCTTGGCAAATCTGGCGTG
 859-MMP1 forward: AGCTGCTACACCTTCAGTGGTGATGTTCA
 859-MMP1 reverse: GATCTGAACATCACCACTGAAGGTGTAGC
 891-MMP1 forward: AGCTCAGGATGACATTGATGGCATCCAAGG
 891-MMP1 reverse: GATCCCTTGGATGCCATCAATGTCATCCTG
2.4. SiRNAs design and chemical synthesis
According to mRNA sequence of human MMP1 (NCBI number:
NM_002421) and the general approach in designing siRNAs for
silencing, 26 segments with 30–50% of GC content and 19–25 nt of
double-stranded siRNAs are preferred. Accordingly, 3 sequences
considering to have high efﬁciency of silencing were synthesized.
Following were the target sequences of siRNA, relative to the
sequence of human MMP1 (NM_002421) in NCBI web.
 Target sequence 506–530 (506 siRNA): AUCUGCUCUUGG-
CAAAUCUGGCGUG
 Target sequence 859–883 (859 siRNA): UGAACAUCACCACU-
GAAGGUGUAGC
 Target sequence 891–915 (891 siRNA): CUUGGAUGCCAUCAAU-
GUCAUCCUG
2.5. Transfection of reporter plasmid and siRNA
The living colors pAcGFP1-N3 vector (Clontech Laboratories,
Inc.) was chosen as report system, which encoding the green
ﬂuorescent protein (GFP) under the CMV promoter. To evaluate the
efﬁciency of siRNAs silencing, 1106 MeWo cells were ﬁrst
inoculated into each well of 24-well plate and cultured in culture
medium for 24h. Following 1mg of reporter plasmid 506-MMP1,
859-MMP1 or 891-MMP1 were transfected individually into the
culturedMeWo cells using XfectTM Transfection Reagent (Clontech
Laboratories, Inc.) and cultured continuously for the next 24h, and
then the designed target siRNA (506 siRNA, 859 siRNA and 891
siRNA) or negative control siRNA (neg-siRNA) were transfected
correspondingly using XfectTM siRNA Transfection Reagent (Clon-
tech Laboratories, Inc.). After cultivation of the following 24h, the
GFP expression was analyzed using Olympus CKX41 ﬂuorescent
microscope and ELISA reader (BioTek synergy HT). Cells with GFP
expression indicated it was successful in construction of target
gene reporter plasmid. Cells with an apparent absence of green
ﬂuorescence indicated gene silencing. Cell viability assay was
performed right after the ﬂuorescent analysis. The protocol of
transfection of reporter plasmid was according to the manufac-
turer’s instruction (Clontech).
2.6. MeWo cells transfected with synthesized siRNA to knockdown
endogenous MMP1 gene
The experiment of knockdown endogenous MMP1 gene was
performed in MeWo cells. MeWo cell is humanmelanoma cell and
the morphology is ﬁbroblast, therefore, it can express the MMP1
protein. Exogenous delivery of siRNA duplexes to mammalian cells
was carried out with the XfectTM siRNA Transfection Reagent
(Clontech Laboratories, Inc.) in a 24 well plate, which was
developed for the delivery of siRNA. Absence of transfection
reagents, siRNA duplexes were not taken up by cells. The protocol
was according to the manufacturer’s instruction (Clontech).
2.7. Western blot analysis
After transfection with 859 siRNA and further 24h incubation,
cells were lysed in a mammalian cell lysis buffer (Clontech
Laboratories, Inc.).Western blot analysiswas thenperformed using
conventional protocols. In brief, protein concentration was
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determined with Bradford assay (Bio-Rad) with bovine serum
albumin as a standard (Sigma). Equal amounts of total proteinwere
then separated on 12% polyacrylamide gels by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then
transferred to polyvinylidene diﬂuoride (PVDF) membrane. Anti-
bodies and dilutions used in this study included anti-MMP1
(1:1000 dilution, Millipore, Billerica, MA, USA) and anti-GAPDH
(1:2000 dilution,Millipore, Billerica, MA, USA). After beingwashed
extensively, the membranes were incubated with goat anti-rabbit
IgG peroxidase conjugate antibody (1:10000 dilution) for 1h at
room temperature and developed with chemiluminescent HRP
substrate (Millipore, Billerica, MA, USA). Membranes probed for
hMMP1were re-probed for GAPDH to normalize for loading and/or
quantiﬁcation errors and to allow comparisons of target protein
expression or inhabitation to bemade. Band density wasmeasured
by photoimage (Fusion-SL2-3500WL, Vilber Lourmat, France,
www.vilber.com).
2.8. Cell viability assay
To detect the potential toxicity to the cell during the experi-
ments, the cell viability was determined in 24 well plates. After
speciﬁed periods of cell incubation (48h post-transfection), 0.5mL
of MTT solution (1.5mg/mL) was added to each well and incubated
at 37 C for 4h. After removal of media, 0.5mL of DMSOwas added
and the absorbance at 540nm was measured. The viabilities were
normalized to the absorbance of non-treated cells.
2.9. Quantitative real-time PCR
The expression of MMP1 mRNAwas analyzed by real time-PCR
assay. After transfection for 24h, total RNA was extracted using
TRIzol Reagent (Invitrogen, Carlsbad, California, USA) with the RNA
quality (UV reader, 260/280 ratio > 1.7) and triplicate assessment
by using microplate (BioTeck, USA). First-strand cDNA was
synthesized using 1mg of total RNA by reverse-transcription using
iScriptTM cDNA synthesis kit (Bio-rad, California) as instructed by
the manufacturer. For real-time PCR analysis of MMP1 and GAPDH
gene expressionwas carried out using iQTM SYBR1Green Supermix
(Bio-rad, California), the primers used were:
 MMP1 forward: AGTCAAGTTTGTGGCTTATGGA
 MMP1 reverse: TTGTCACTGAAGCTGCTCTC
 GAPDH forward: GTCGGAGTCAACGGATTT
 GAPDH reverse: CAACAATATCCACTTTACCAGAG
Brieﬂy, the reaction mixture containing 2mL cDNA, 1mL
forward primer (0.5mM), 1mL reverse primer (0.5mM), 10mL iQ
SYBR Green Supermix, and 6mL RNase-free water was prepared.
The real-time PCR programwas set as follows: initial denaturation
at 95 C for 3min, followed by 40 cycles of 95 C for 10 s, and then
61 C for 30 s. Finally, the melting curve programwas performed at
the end of each reaction. The relative levels of mRNA expression
was assessed by the comparative Ct method (DDCT method),
which normalize the mRNA level of negative control to that of
reference gene GAPDH.
3. Results and discussion
3.1. Human MMP1 cDNA synthesis and construction of MMP1 target
gene reporter plasmid
To construct MMP1 target reporter plasmid, as shown in Fig. 1,
the MMP1 cDNA (sequence 150–953) fused with Kozak sequence
[15,4] at 50-end to initiate translation process and incorporated 2
restriction sites to facilitate subcloning reactionwas ﬁrst ampliﬁed
(831 bp fragment) by PCR (Fig. 2) and subcloned into pAcGFP1-N3
vector, using HindIII and BamHI cutting sites, downstream the
immediate early promoter of CMV (PCMV IE) and followed in frame
by the green ﬂuorescent protein AcGFP1 coding sequences.
Although the partial MMP1-AcGFP1 fusion DNA could be
transcribed under control of CMV promoter, and translated by
Kozak sequence, the ﬂuorescent intensity was not satisﬁed (data
not shown). It might be because the molecular of N-terminal fused
MMP1 partial protein was too large, which consequently affected
the green ﬂuorescent protein folding or its function. To overcome
this issue, three potent siRNA target DNAs, 506-MMP1, 859-MMP1
and 891-MMP1 as shown in Fig. 1B–D, were constructed
[(Fig._2)TD$FIG]
Fig. 2. Agarose gel analysis of PCR product of human ﬁbroblast cell MMP1 cDNA.
Lane M: 100bp DNAmarker; lane 1: PCR product (MMP1831bp), EtBr staining was
carried out after electrophoresis in a 1.5% agarose gel.
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individually to pAcGFP1-N3 plasmid. Since the length of target
gene was about 25–26bp, forward and reward oligonucleotides
were annealed by cooling down from95 C to 50 C in PCRmachine
to form a double strand and ligated to pAcGFP1-N3 vector, which
was precut by HindIII and BamHI. As shown in Fig. 1B, the 506-
MMP1 (sequence 506–530) had no translation initiation codon
“ATG” and its last 2 codes were “AT”. One cytidylic acid “C” was
extended at the 30-end of 506-MMP1F0 oligonucleotide, as
indicated by “q”, to avoid translation initiation codon “ATG” been
created after ligated with BamHI, since the created “ATG”would be
used as translation initiation codon, and frame shift mutation
would happen in the following codons of AcGFP1. As shown in
Fig.1C andD, the “ATG” codonwas existed in 506-MMP1 (sequence
506–530) and 859-MMP1 (sequence 859–883) DNA sequences, as
indicated by border, and would be used as translation initiation
codon for expression of the N-MMP1 oligopeptide- AcGFP1 fusion
ﬂuorescence proteins. As shown in Fig. 1D, one guanylic acid “G”
extended at the 30-end of 891-MMP1F0 oligonucleotide, as
indicated by “s”, was designed to avoid frame shift mutation in
the following codons of AcGFP1.
3.2. Optimal transfection concentration of reporter plasmid and
suitable time for ﬂuorescence assay
To determine the optimal transfection concentration of reporter
plasmid and suitable time for ﬂuorescence assay, the MeWo cells
were treated with 25mL XfectTM Transfection Reagent. The
ﬂuorescent expression of cells at 24, 48 and 72h post transfection
of 506-MMP1-pAcGFP1-N3 increased with the duration of
incubation time (Fig. 3). Nevertheless, it increased with the
increase of vector concentration (0.5, 0.75, 1.0, and 1.5mg) (Fig. 4).
According to the data obtained, the highest ﬂuorescent intension
was observed at 72h incubation time, while the optimal
concentration for the reporter vector concentration was 1.0mg.
Although the 72h was determined to be the optimal time, the 48h
also had considerable ﬂuorescent intensity for the following
interfering experiments. To avoid contamination during cell
cultivation and for the consideration of cell life-time, 48h
incubation time and 1.0mg of the reporter vector concentration
was chosen for the following experiments.
3.3. Estimation of MMP1 gene silencing efﬁcacy by siRNAs using
reporter system
MMP1 partial cDNA-pAcGFP1-N3, 506-MMP1-pAcGFP1-N3
(506 plasmid), 859-MMP1- pAcGFP1-N3 (859 plasmid), and
891-MMP1- pAcGFP1-N3 (891 plasmid) plasmids were used to
evaluate the gene silencing efﬁcacy according to intensity of green
ﬂuorescence expressed from these reporter systems. The 506, 859,
and 891 plasmids, target 506 siRNA, 859 siRNA, 891 siRNA, and a
negative control siRNA (neg siRNA) (Invitrogen) with GC content of
48% (similar to that of target siRNA between 45% and 55%) were
transfected separately into MeWo cells. Since XfectTM Transfection
Reagent would cause cells toxicity and affect ﬂuorescent expres-
sion, cell viability was examined by MTT reagent right after the
treatment of ﬂuorescent assay to exclude deviation. The
[(Fig._3)TD$FIG]
Fig. 3. The image of the ﬂuorescent intensity and cell number of MeWo cell transfected with 0.5mg of 506-MMP1-pAcGFP1-N3 reporter plasmid by Xfect reagent and
cultured for 24, 48 and 72h. A–C are the light micrographs taken at 24, 48 and 72h after transfection, respectively. D–F are the ﬂuorescence images corresponding to A–C. All
the micrographs were taken using Olympus CKX41 ﬂuorescent microscope.
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ﬂuorescent expression of each cell was obtained from the
ﬂuorescent expression divided by cell viability, and the ﬂuorescent
expression of control group (no siRNA) was used as background to
ensure non-speciﬁc complementation or other genes inhibition.
Furthermore, to emphasize that the designed target siRNAs
caused the inﬂuence effect, the MeWo cells transfected with
different concentrations of neg siRNA were assayed. According to
the ﬂuorescent photos and the statistical data of the results, no
[(Fig._4)TD$FIG]
Fig. 4. The optimal transfection concentration of 506-MMP1- pAcGFP1-N3 reporter plasmid and suitable time for ﬂuorescence assay. The ﬂuorescent intensity of the MeWo
cells transfected with different concentration (0.5, 0.75, 1.0 and 1.5mg) of 506-MMP1-pAcGFP1-N3 reporter plasmid by Xfect reagent and cultured for 24, 48 and 72h was
quantiﬁed using ELISA reader (BioTek synergy HT). The wavelengths of excitation and emission were 475 and 505nm, respectively.
[(Fig._5)TD$FIG]
Fig. 5. Fluorescent micrographs of MeWo cells, transfected with target gene reporter plasmid (506 plasmid, 859 plasmid or 891 plasmid) and target siRNA (506 siRNA, 859
siRNA, 891 siRNA) or neg siRNA. These ﬂuorescentmicrographswere taken at 48h post-transfection. (A) MeWo cells were ﬁrst transfectedwith 1mg of individual target gene
reporter plasmid, and incubation for 24h following transfectedwith different concentration (0,10, 30, 50, 70, 90nM) of neg siRNA. After further incubation of 24h, theMeWo
cells were analyzed for GFP expression. (B) All the transfection and cultivation conditions were the same as (A), but replaced the neg siRNA as individual designed target
siRNA. All the micrographs were taken using Olympus CKX41 ﬂuorescent microscope.
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signiﬁcant changes in ﬂuorescent intensity and cell survival rate of
MeWo cells transfected with different concentrations of neg siRNA
was obtained (Fig. 5A and Fig. 6). However, when treated with the
designed target siRNA, the ﬂuorescent expression decreased with
the increase of siRNA concentration and the inﬂuence efﬁciency
was more signiﬁcant (Fig. 5B and Fig. 6), suggesting it was dose-
dependent. These phenomena suggested that these three target
siRNAs were able to speciﬁcally and distinctly silence the
endogenous MMP1 gene expression. According to the data
obtained, the inhibition of 506 siRNA was 39.2%, while those of
859 siRNA and 891 siRNA were 89.4% and 54.1%, respectively
(Fig. 6). The best interference effect was observed on 859 siRNA, up
to 89.4% of inhibition rate.
3.4. Quantitative PCR analysis of the interference efﬁcacy of various
concentrations siRNAs on endogenous MMP1 gene expression
Ishii et al. [10] reported thatMeWo ﬁbroblast cell (BCRC 60540),
a kinds of human melanoma cells, can express spontaneously the
endogenous MMP1 protein, and the expression quantity could be
enhanced by exposure to nitric oxide (NO) or S-nitroso-N-acetyl-
DL-penicillamine (SNAP) in a dose-dependent manner. Therefore,
the MeWo cells were employed as target cells in quantitative PCR
and western blot analysis to investigate whether the evaluation of
effective designed siRNAs by the GFP reporter systems was able to
interferewith the expression ofMMP1mRNAor protein. According
to the results of preliminary experiments, Figs. 7 and 8, the
expression quantity and the siRNA interfering efﬁciency of
endogenous mRNA or protein of MMP1 in MeWo cells without
induction by NO or SNAP was visible in the blanks (without siRNA
treatment). Accordingly, the MeWo cells used in this study were
not treated with NO or SNAP to avoid inﬂuence by other factors.
To conﬁrm the interference efﬁcacy of siRNAs against endoge-
nous MMP1 gene expression in MeWo cells, the quantitative PCR
(real-time PCR) was prepared. The MeWo cells were transfected
with various concentrations (10, 30, 50, 70 or 90nM) of 506 siRNA,
859 siRNA and 891 siRNA, separately. The total RNA was extracted
and cDNA were synthesized as described in the methodology.
The remained MMP1 mRNA was analyzed by real-time quantita-
tive polymerase chain reaction (RT-PCR) and agarose gel electro-
phoresis analysis.
According to the results of preliminary experiments, when the
concentration of any one of the three designed siRNAs was higher
than 100pmol, the interference efﬁcacy was not consistent and
had high standard deviation between repetitive experiments (data
not shown). This might be attributed to short half-life and
instability of siRNAs. The phenomenon was similar to [11], they
had suggested that when the concentration of siRNA was higher
than 100nM, it could cause off-target effect, resulting in the error
judgments of the experimental results, so in this study, all the
concentration of siRNA used in different tests was ranged from 10
to 90nM.
As shown in Fig. 7, the endogenous MMP1 mRNA could be
interfered with 506 siRNA and 859 siRNA, but the interference
[(Fig._6)TD$FIG]
Fig. 6. The statistical analysis of the interfering efﬁciency of target designed siRNAusing the GFP reporter system. TheMeWo cells transfected successively (with an interval of
24h) with target gene reporter plasmid (506 plasmid (A), 859 plasmid (B) or 891 plasmid (C)) and neg siRNA or target siRNA (506 siRNA (A), 859 siRNA (B) or 891 siRNA (C))
were used as reporter system. All the transfection and cultivation conditions were the same as Fig. 5. MeWo cells transfected with 1mg target gene reporter plasmid and
different concentration (0,10, 30, 50, 70, 90nM) of neg siRNAor target designed siRNA. After further incubation for 24h, cells were analyzed for the ﬂuorescent intensity using
ELISA reader (BioTek synergy HT) and cell viability by MTT assay.
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efﬁcacy of various concentrations of siRNAs on endogenous MMP1
gene expression were not dose-dependent. The inhibition rates of
506 siRNA and 859 siRNA against endogenous MMP1 gene
expression were 55% and 85%, respectively (Fig. 7). Regarding to
the 891 siRNA, its interference efﬁcacy was not constant, dose-
dependent with large standard deviation among many repetitive
experiments (data not shown). It was, therefore, not included in
Fig. 7. Thismight be attributed to instability of the 891 siRNAs, non-
speciﬁc complementation or other unknown siRNA interfering
progress. According to the above results of quantitative PCR, the
859 siRNA had better interference efﬁciency on endogenousMMP1
gene expression in MeWo cells, and consequently been proceeded
the following western blot analysis.
3.5. Western blot analysis of protein silencing
The inhibition rates of 859 siRNA against endogenous MMP1
gene expression in MeWo cells transfected with various concen-
trations of 859 siRNA (10, 30, 50, 70 or 90nM) were determined
and found that 90nM of 859 siRNA had highest inhibition rate,
89.4%, on endogenous MMP1 protein expression (Fig. 8).
Whereas many study had focused and proved on factors
affecting siRNA interfering efﬁciency [1,27,12,14,20], and many
software for design and prediction of siRNA [5,9,17,30] have been
developed. In this study, the MMP1-pAcGFP1-N3 reporter/MeWo
cells reporter system had been created and the interference
efﬁcacy of three novel designed siRNAs against MMP1 had been
evaluated. According to the results of MMP1-pAcGFP1-N3/MeWo
cells reporter system, all the three target siRNAs were able to
silence the target MMP1- GFP fused gene expression and the
inhibition rate of 506 siRNA, 859 siRNA and 891 siRNAwere 39.2%,
89.4% and 54.1%, respectively. The 859 siRNA exhibited the highest
gene silencing activity in 859-MMP1- pAcGFP1-N3 reporter
system. Further conﬁrmation of the interference efﬁcacy of the
859 siRNA against endogenous MMP1 gene expression was
performed in MeWo cells using quantitative PCR (Fig. 7) and
western blot (Fig. 8) analyses. It exhibited 85 (quantitative PCR)
and 89% (western blot) inhibition rates of endogenous MMP1 gene
and protein expression, respectively. These results were in
accordance with the assay by MMP1-pAcGFP1-N3/MeWo cells
reporter system, suggesting that the data evaluated by the reporter
systemwere reliable, although it is regrettable that the longMMP1
partial cDNA-AcGFP1-N3 reporter plasmid (Fig. 1A), contained all
three siRNA target DNAs, is not suitable.
These data not only provide the basic data for siRNA technology,
but also obtain the small interfering RNAs (siRNA or shRNA) with
inhibition of matrix metalloproteinase 1 (MMP1) gene expression.
In the future, the 859 siRNAmay be applied as anti-wrinkle reagent
in cosmetic industry and anti-tumor metastasis reagents in
medical applications, and it is actually on-going in our laboratory,
currently.
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